Effects of Cannabidiol on TAFAZZIN ‐Deficient B‐Lymphoblastoid Cells
The FASEB Journal · 31.03.2026 · 40 (6)
DOI: 10.1096/fj.202503384r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 13.03.2026. Verfasst von John Z Chan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology and Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Barth Syndrome, Transcription Factors, Cannabidiol, B-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC), Barth Syndrome Foundation of Canada, Canada Foundation for Innovation.
Abstract (Originalsprache)
Barth Syndrome (BTHS) is a debilitating X‐linked genetic disorder caused by mutations in the gene encoding TAFAZZIN, an enzyme responsible for the remodeling of cardiolipin. While cyclic neutropenia is a well‐recognized immunological feature of this disease, emerging evidence suggests that lymphopenia may also occur. The objective of this study was to examine the effects of cannabidiol (CBD) on growth, cardiolipin content, and mitochondrial abnormalities in BTHS patient‐derived B‐lymphoblastoid cells. CBD (1 μM) restored the growth of BTHS B‐lymphoblastoids to healthy control levels, but did not alter cell cycle distribution or sub‐G1 cell populations, which surprisingly also did not differ from healthy control B‐lymphoblastoids. CBD treatment also fully restored the total cellular cardiolipin concentration and reversed the elevation in monolysocardiolipin/cardiolipin ratio in BTHS B‐lymphoblastoids to healthy cell levels, but did not restore the cardiolipin fatty acyl composition. Assessment of mitochondrial markers suggested that increased cardiolipin did not result from increased mitochondrial content. This improvement in cardiolipin concentration was associated with a significant increase in the maximal coupled state III respiration of BTHS B‐lymphoblastoids, with all five tested BTHS donors exhibiting increased mitochondrial membrane potential following CBD treatment. CBD fully reversed the deficit in succinate dehydrogenase subunit A in BTHS cells, and partially reversed deficits in cytochrome c oxidase subunits I and IV, and partially restored supercomplex I/III 2 levels, but did not rescue I/III 2 /IV levels. This work suggested a potential role for CBD as a therapeutic in BTHS B‐lymphopenia that merits further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Kinesiology and Health Sciences, Faculty of Health, University of Waterloo, Waterloo, Ontario, Canada.
ORCID-Profile: Joe Quadrilatero, Robin E Duncan
Förderung
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Barth Syndrome Foundation of Canada
- Canada Foundation for Innovation
- Goverment of Ontario
Zitieren
APA
Chan, J. Z., Berdeklis, A. N., Liu, M. R., Rahman, F. A., Tomczewski, M. V., Graham, M. Q., Musa, M., Cocco, A. D., Stark, K. D., Quadrilatero, J., & Duncan, R. E. (2026). Effects of Cannabidiol on TAFAZZIN ‐Deficient B‐Lymphoblastoid Cells. The FASEB Journal, 40(6). https://doi.org/10.1096/fj.202503384r
Vancouver
Chan JZ, Berdeklis AN, Liu MR, Rahman FA, Tomczewski MV, Graham MQ, et al. Effects of Cannabidiol on TAFAZZIN ‐Deficient B‐Lymphoblastoid Cells. The FASEB Journal. 2026;40(6). doi:10.1096/fj.202503384r
BibTeX
@article{Chan2026,
author = {Chan, John Z and Berdeklis, Antonia N and Liu, Ming Rong and Rahman, Fasih A and Tomczewski, Michelle V and Graham, Mackenzie Q and Musa, Musa and Cocco, Alex D and Stark, Ken D and Quadrilatero, Joe and Duncan, Robin E},
title = {Effects of Cannabidiol on TAFAZZIN ‐Deficient B‐Lymphoblastoid Cells},
journal = {The FASEB Journal},
year = {2026},
volume = {40},
number = {6},
doi = {10.1096/fj.202503384r}
}
EUVIMED